Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12275897 | 0.95 | SMN1; SMN2 (0.36) | CA2ALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL502096 | 0.92 | ALDH1A1 (0.34) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL15994679 | 0.89 | CA2 (0.37) | CA2CA1ALDH1A1CYP1A2HPGD | |
| SCHEMBL92976 | 0.89 | CA2 (0.37) | CA2CA1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3735742 | 0.86 | ALDH1A1 (0.36) | CA2CA1ALDH1A1CYP1A2HPGD | |
| SCHEMBL11129630 | 0.83 | SMN1; SMN2 (0.31) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL23802513 | 0.81 | CA2 (0.43) | CA2CA1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5165284 | 0.80 | GSK3A (0.44) | CA2CA1ALDH1A1CYP1A2HPGD | |
| SCHEMBL5165799 | 0.80 | CA2 (0.46) | CA2CA1ALDH1A1CYP1A2HPGD | |
| SCHEMBL17883835 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688828-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | Jubilant DraxImage Inc. (CA) | 2026-02-11 | — | — | EP | claimed |
| WO-2024201255-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | JUBILANT DRAXIMAGE INC. (CA) | 2024-10-03 | — | — | WO | claimed |
| US-20240316226-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | JUBILANT DRAXIMAGE INC. (CA) | 2024-09-26 | — | — | US | claimed |
| WO-2023129438-A1 | HYDROGEL COMPOSITIONS FOR USE FOR DEPLETION OF TUMOR ASSOCIATED MACROPHAGES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-07-06 | — | — | WO | claimed |
| EP-0526700-A2 | Drug-containing protein-bonded liposome | Mitsubishi Chemical Corporation (JP) | 1993-02-10 | — | — | EP | claimed |
| US-20260147001-A1 | PROTEIN SEQUENCING VIA COUPLING OF POLYMERIZABLE MOLECULES | GLYPHIC BIOTECHNOLOGIES, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260118364-A1 | PROTEIN SEQUENCING VIA COUPLING OF POLYMERIZABLE MOLECULES | GLYPHIC BIOTECHNOLOGIES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | GLYPHIC BIOTECHNOLOGIES INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12539339-B2 | Radiopharmaceutical conjugate compound for diagnosis and/or therapeutic uses thereof | JUBILANT DRAXIMAGE INC. (IN) | 2026-02-03 | — | — | US | disclosed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4657067-A2 | MOLECULES AND METHODS FOR IMPROVED IMMUNODETECTION OF SMALL MOLECULES, SUCH AS HISTAMINE | President And Fellows Of Harvard College (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250327811-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING DITHIOESTER AND THIOCARBAMOYL AMINO ACID REACTIVE GROUPS | GLYPHIC BIOTECHNOLOGIES, INC. | 2025-10-23 | — | — | US | disclosed |
| US-20010016333-A1 | Novel protein and monoclonal antibody specific thereto | DAIICHI FINE CHEMICAL CO., LTD. (JP) | 2001-08-23 | — | — | US | disclosed |
| US-5442043-A | Penetration brain-blood barrier; drug delivery | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-08-15 | — | — | US | disclosed |
| EP-0599303-A2 | Peptide conjugate | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-06-01 | — | — | EP | disclosed |
| EP-0526700-A2 | Drug-containing protein-bonded liposome | Mitsubishi Chemical Corporation (JP) | 1993-02-10 | — | — | EP | disclosed |
| US-5137807-A | Measuring enzyme activity of bound antibody antigen enzyme-labeled antibody complex | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1992-08-11 | — | — | US | disclosed |
| EP-0401370-A1 | ENZYME IMMUNOASSAY ACCORDING TO SANDWICH METHOD OF HUMAN IV-TYPE COLLAGEN | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1990-12-12 | — | — | EP | disclosed |
| EP-0152736-A2 | Enzyme-protein conjugate, process for its preparation and pharmaceutical composition | BEECHAM GROUP PLC (GB) | 1985-08-28 | — | — | EP | disclosed |
| EP-0144084-A2 | Reagent for immunoassay and analytical method using the same | KABUSHIKI KAISHA TOSHIBA (JP) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539339-B2 | Radiopharmaceutical conjugate compound for diagnosis and/or therapeutic uses thereof | SLC7A1, SLC39A11, SLC39A3 | CA2 253/4885CA1 18/4885ALDH1A1 778/4885 |
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | CHAMP1, S100A11, TFIP11 | CA2 2680/4885CA1 4103/4885ALDH1A1 4748/4885 |
| US-20260118364-A1 | PROTEIN SEQUENCING VIA COUPLING OF POLYMERIZABLE MOLECULES | SPPL2B, SPPL2A, MAX | CA2 3600/4885CA1 3184/4885ALDH1A1 4750/4885 |
| US-20260147001-A1 | PROTEIN SEQUENCING VIA COUPLING OF POLYMERIZABLE MOLECULES | SPPL2A, SPPL2B, PTMS | CA2 3061/4885CA1 2492/4885ALDH1A1 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.